Clinical Trial Details
— Status: Not yet recruiting
Administrative data
| NCT number |
NCT05943093 |
| Other study ID # |
PCR in acute leukemia |
| Secondary ID |
|
| Status |
Not yet recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
July 2023 |
| Est. completion date |
August 2025 |
Study information
| Verified date |
July 2023 |
| Source |
Assiut University |
| Contact |
Fatma Refaat Ibrahim |
| Phone |
01032073035 |
| Email |
drfatmarefaat[@]gmail.com |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
- Study the expression level of H19 gene in the samples from ALL patients by real-time
PCR.
- Correlate the expression level of H19 gene with the clinical presentation and laboratory
data of those patients.
Description:
Acute lymphoblastic leukemia (ALL) is the most common cancer affecting children and
adolescents (Zeng XL et al, 2023). ALL is a haematological malignancy characterized by the
malignant clonal expansion of lymphoid hematopoietic precursors (Hong Z et al, 2021). It
arises from B- or T-lineage lymphoid progenitors: B-cell-precursor ALL (B-ALL) and T-cell ALL
(T-ALL) (Brady SW et al., 2022). Rrelapse in ALL is the fundamental cause of treatment
failure in 15-20% of patients (Hulleman E et al, 2009). Therefore, the exploration of novel
functional molecules that play a role in ALL pathogenesis could be effective therapeutic
targets for this disease (Asadi M et al, 2023).
Long non-coding RNAs (lncRNAs) are non-protein coding transcripts longer than 200 nucleotides
(Kopp F et al, 2018). H19 was the first lncRNA to be discovered and submitted for genomic
imprinting (Yoshimura H et al, 2018). It has a role in embryogenesis and tumorigenesis
(Yoshimura H et al, 2014). It also has an indispensable role in enhancing cell proliferation,
differentiation, migration, invasion, and chemo resistance (Li Y et al, 2020). Recent
evidence has shown that H19 is an oncogene and is overexpressed in breast, liver,
endometrial, lung, cervical, and esophageal cancers (Asadi M et al, 2023). A similar pattern
of H19 expression was observed in various types of leukemias, including chronic myeloid
leukemia (CML) (Morlando M et al, 2015) and acute myeloid leukemia (AML) (Zhang Tj et al,
2018).
